MarkStephenGelderMD

Obstetrics & Gynecology • Phoenixville, PA

Gynecologic Oncology, Urogynecology & Pelvic Reconstructive Surgery

SVP & Chief Medical Officer Heron Therapeutics

Join to view full profile

Dr. Gelder is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gelder's full profile

Already have an account?

Office
200 Rivercrest Drive
Phoenixville, PA 19460

Education & Training

University of Virginia School of MedicineClass of 1982

Clinical Trials

A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC Start of enrollment: 2014 Mar 01
Completed
Phase 3

Publications & Presentations

PubMed

25 citations
Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron.
Thomas Ottoboni, Mark S Gelder, Erin O’Boyle
Journal of Experimental Pharmacology. 2014-12-09

Press Mentions

Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark GelderApril 6th, 2023
Onconova Therapeutics Provides an Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS Non-Small Cell Lung CancerJune 28th, 2021
Two Months After Inking a SPAC Deal, Renovacor Taps New CMO; CureVac Reels in a New Development Chief from Merck KGaAJune 4th, 2021
Join now to see all